Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Decheng Capital
BioCentury | Dec 19, 2024
Emerging Company Profile
Ottimo: Differentiating from the VEGF bispecific pack via VEGFR-2
Newco, led by ex-Seagen CEO Epstein, announces $140M series A
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Oct 11, 2024
Finance
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception
BioCentury’s weekly Public Equity Report also includes financings by Crinetics, Scholar Rock, Immatics, Inhibikase and Vicore
BioCentury | Sep 20, 2024
Finance
Upstream enters IPO queue; Nuvalent follow-on balloons to $575M
Also in BioCentury’s weekly Public Equity Report: Ascendis follows up a data release with a $300M offering; BioAge proposes terms for listing
BioCentury | May 9, 2024
Finance
Venture report: Big rounds for Bluejay, Attovia and Zenas
Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
BioCentury | Feb 16, 2024
Finance
Venture report: Earlybird’s €173M fund, launches for Firefly and Latigo
European VC closes new vehicle; start-ups backed by Versant, Westlake Village out of stealth; Medicxi’s bundle; rounds for Freenome, ProfoundBio
BioCentury | Jan 4, 2024
Finance
Jan. 3 Quick Takes: Goldman Sachs unveils $650M life sciences fund
Plus: Arrowhead trades up as $450M follow-on extends runway and updates from Remix, CG Oncology, Agios, Boehringer-Ribo, Enyo
BioCentury | Dec 5, 2023
Product Development
Dec. 4 Quick Takes: EyePoint’s data for Eylea competitor drive big gain
Plus: Seismic adds $121M in series B round and updates from Merck KGaA, Abbisko, Perpetual Medicines, CRISPR Therapeutics and YolTech
BioCentury | Sep 25, 2023
Product Development
Sept. 25 Quick Takes: Novartis’ Lutathera meets primary for first-line GEP-NETs
Plus: Japan’s latest drug approvals and updates from Junshi, Adela, AbbVie, I-Mab, Novo, Valo, BridgeBio, GSK, Scynexis
BioCentury | Sep 8, 2023
Deals
Sept. 8 Quick Takes: Appeals court backs physicians who prescribed ivermectin
Plus: Shanghai TIL play Grit closes $60M B round and deals by Alexion-Verge, Shape-Otsuka and more
Items per page:
1 - 10 of 93